Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry


ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Research Article

Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis

Author(s): Liang Cheng, Tao Qin, Jiguang Ma, Wanxing Duan, Qinhong Xu, Xuqi Li, Liang Han, Wei Li, Zheng Wang, Dong Zhang, Qingyong Ma* and Jianjun Lei*

Volume 19 , Issue 12 , 2019

Page: [1503 - 1512] Pages: 10

DOI: 10.2174/1871520619666190626120359

Price: $65


Background: Recent studies have suggested that 85% of pancreatic cancer patients accompanied with impaired glucose tolerance or even Diabetes Mellitus (DM) and the invasive and migratory abilities of pancreatic cancer could be enhanced by high glucose. This study aimed to investigate whether Hypoxia- Inducible Factor-1α (HIF-1α) mediates hyperglycemia-induced pancreatic cancer glycolysis.

Methods: The cellular glycolytic activity was assessed by determining lactate production, glucose uptake and lactate dehydrogenase enzymatic activity. Pancreatic cancer cells (BxPC-3 cells) were transfected with short hairpin RNA targeting the HIF-1α.

Results: Hyperglycemia promotes pancreatic cancer glycolysis. Lactate dehydrogenase A (LDHA) activity and hexokinase 2 (HK2), platelet-type of phosphofructokinase (PFKP) expression were significantly upregulated under hyperglycemic conditions. HIF-1α knockdown prominently down-regulated the activity of LDHA and the expression of HK2, PFKP and decreased lactate production in BxPC-3 cells. Under hypoxia condition, hyperglycemia induced pancreatic glycolysis by mechanisms that are both dependent on HIF-1α and independent of it.

Conclusion: The accumulation of HIF-1α induced by hyperglycemia increases LDHA activity and HK2, PFKP expression, thereby promoting pancreatic glycolysis to facilitate cancer progression.

Keywords: Hyperglycemia, lactate dehydrogenase A, HIF-1α, glycolysis, pancreatic cancer.

Graphical Abstract
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2018. CA Cancer J. Clin., 2018, 68(1), 7-30.
Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global Cancer Statistics, 2012. CA Cancer J. Clin., 2015, 65(2), 87-108.
Chen, W.Q.; Zheng, R.S.; Baade, P.D.; Zhang, S.W.; Zeng, H.M.; Bray, F.; Jemal, A.; Yu, X.Q.; He, J. Cancer Statistics in China, 2015. CA Cancer J. Clin., 2016, 66(2), 115-132.
Parkin, A.; Man, J.; Chou, A.; Nagrial, A.M.; Samra, J.; Gill, A.J.; Timpson, P.; Pajic, M. The evolving understanding of the molecular and therapeutic landscape of pancreatic ductal adenocarcinoma. Diseases, 2018, 6(4)E103
Cameron, M.E.; Yakovenko, A.; Trevino, J.G. Glucose and lactate transport in pancreatic cancer: Glycolytic metabolism revisited. J. Oncol., 2018, 20186214838
Ben, Q.W.; Xu, M.J.; Ning, X.Y.; Liu, J.; Hong, S.Y.; Huang, W.; Zhang, H.G.; Li, Z.S. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur. J. Cancer, 2011, 47(13), 1928-1937.
Esposito, K.; Chiodini, P.; Colao, A.; Lenzi, A.; Giugliano, D. Metabolic Syndrome and risk of cancer a systematic review and meta-analysis. Diabetes Care, 2012, 35(11), 2402-2411.
Ren, H.B.; Yu, T.; Liu, C.; Li, Y.Q. Diabetes mellitus and increased risk of biliary tract cancer: Systematic review and meta-analysis. Cancer Causes Control, 2011, 22(6), 837-847.
Wu, L.; Yu, C.; Jiang, H.; Tang, J.; Huang, H.L.; Gao, J.; Zhang, X. Diabetes mellitus and the occurrence of colorectal cancer: An updated meta-analysis of cohort studies. Diabetes Technol. Ther., 2013, 15(5), 419-427.
Li, W.; Ma, Q.Y.; Liu, J.B.; Han, L.; Ma, G.D.; Liu, H.; Shan, T.; Xie, K.P.; Wu, E.X. Hyperglycemia as a mechanism of pancreatic cancer metastasis. Front. Biosci-Landmrk., 2012, 17, 1761-1774.
Han, L.; Ma, Q.Y.; Li, J.H.; Liu, H.; Li, W.; Ma, G.D.; Xu, Q.H.; Zhou, S.; Wu, E.X. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One, 2011, 6(11)e27074
Li, W.; Ma, Q.Y.; Li, J.H.; Guo, K.; Liu, H.; Han, L.; Ma, G.D. Hyperglycemia enhances the invasive and migratory activity of pancreatic cancer cells via hydrogen peroxide. Oncol. Rep., 2011, 25(5), 1279-1287.
Li, W.; Ma, Z.H.; Ma, J.G.; Li, X.Q.; Xu, Q.H.; Duan, W.X.; Chen, X.; Lv, Y.F.; Zhou, S.; Wu, E.X.; Ma, Q.Y.; Huo, X.W. Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer. Oncotarget, 2015, 6(31), 31119-31133.
Li, J.H.; Ma, Q.Y.; Liu, H.; Guo, K.; Li, F.; Li, W.; Han, L.A.; Wang, F.F.; Wu, E.X. Relationship between neural alteration and perineural invasion in pancreatic cancer patients with hyperglycemia. PLoS One, 2011, 6(2)e17385
Prochazka, B.; Qureshi, M.A.; Matty, A.J. Lactate dehydrogenase activity and isoenzyme patterns in skeletal muscle, fat, exocrine pancreas and isolated pancreatic islets of normal and obese-hyperglycaemic mice. Diabetologia, 1970, 6(5), 493-498.
Li, J.; Zhu, S.C.; Tong, J.; Hao, H.; Yang, J.; Liu, Z.K.; Wang, Y.X. Suppression of lactate dehydrogenase A compromises tumor progression by downregulation of the Warburg effect in glioblastoma. Neuroreport, 2016, 27(2), 110-115.
Rajeshkumar, N.V.; Dutta, P.; Yabuuchi, S.; de Wilde, R.F.; Martinez, G.V.; Le, A.; Kamphorst, J.J.; Rabinowitz, J.D.; Jain, S.K.; Hidalgo, M.; Dang, C.V.; Gillies, R.J.; Maitra, A. Therapeutic targeting of the warburg effect in pancreatic cancer relies on an absence of p53 function. Cancer Res., 2015, 75(16), 3355-3364.
Dai, Q.S.; Yin, Q.; Wei, L.B.; Zhou, Y.X.; Qiao, C.; Guo, Y.J.; Wang, X.T.; Ma, S.P.; Lu, N. Oroxylin A regulates glucose metabolism in response to hypoxic stress with the involvement of Hypoxia-inducible factor-1 in human hepatoma HepG2 cells. Mol. Carcinog., 2016, 55(8), 1275-1289.
DeBerardinis, R.J.; Chandel, N.S. Fundamentals of cancer metabolism. Sci. Adv., 2016, 2(5)e1600200
Yang, W.W.; Zheng, Y.H.; Xia, Y.; Ji, H.T.; Chen, X.M.; Guo, F.; Lyssiotis, C.A.; Aldape, K.; Cantley, L.C.; Liu, Z.M. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol., 2012, 14(12), 1295-1304.
Girgis, H.; Masui, O.; White, N.M.A.; Scorilas, A.; Rotondo, F.; Seivwright, A.; Gabril, M.; Filter, E.R.; Girgis, A.H.A.; Bjarnason, G.A.; Jewett, M.A.S.; Evans, A.; Al-Haddad, S.; Siu, K.W.M.; Yousef, G.M. Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Mol. Cancer, 2014, 13, 101.
Sheng, S.L.; Liu, J.J.; Dai, Y.H.; Sun, X.G.; Xiong, X.P.; Huang, G. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. FEBS J., 2012, 279(20), 3898-3910.
Cai, Z.; Zhao, J.S.; Li, J.J.; Peng, D.N.; Wang, X.Y.; Chen, T.L.; Qiu, Y.P.; Chen, P.P.; Li, W.J.; Xu, L.Y.; Li, E.M.; Tam, J.P.M.; Qi, R.Z.; Jia, W.; Xie, D. A combined proteomics and metabolomics profiling of gastric cardia cancer reveals characteristic dysregulations in glucose metabolism. Mol. Cell. Proteomics, 2010, 9(12), 2617-2628.
Fritz, P.J. Rabbit muscle lactate dehydrogenase 5 - A regulatory enzyme. Science, 1965, 150(3694), 364-366.
Semenza, G.L.; Jiang, B.H.; Leung, S.W.; Passantino, R.; Concordet, J.P.; Maire, P.; Giallongo, A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem., 1996, 271(51), 32529-32537.
Liang, X.J.; Liu, L.; Fu, T.T.; Zhou, Q.; Zhou, D.X.; Xiao, L.W.; Liu, J.; Kong, Y.; Xie, H.; Yi, F.C.; Lai, L.; Vega, R.B.; Kelly, D.P.; Smith, S.R.; Gan, Z.J. Exercise inducible lactate dehydrogenase B regulates mitochondrial function in skeletal muscle. J. Biol. Chem., 2016, 291(49), 25306-25318.
Pertega-Gomes, N.; Felisbino, S.; Massie, C.E.; Vizcaino, J.R.; Coelho, R.; Sandi, C.; Simoes-Sousa, S.; Jurmeister, S.; Ramos-Montoya, A.; Asim, M.; Tran, M.; Oliveira, E.; da Cunha, A.L.; Maximo, V.; Baltazar, F.; Neal, D.E.; Fryer, L.G.D. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: A role for monocarboxylate transporters as metabolic targets for therapy. J. Pathol., 2015, 236(4), 517-530.
Mraz, J.; Vrubel, F.; Hanselova, M. Carcinoma of the prostate. II. Serum activity of acid phosphatase, prostatic acid phosphatase, LDH and its isoenzymes. Int. Urol. Nephrol., 1979, 11(4), 301-309.
Vrubel, F.; Mraz, J.; Nemecek, R.; Papousek, F.; Hanselova, M. Carcinoma of the prostate. I. Histochemical examination as an aid in evaluating prostate carcinoma. Int. Urol. Nephrol., 1979, 11(4), 295-299.
Mathupala, S.P.; Rempel, A.; Pedersen, P.L. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J. Biol. Chem., 2001, 276(46), 43407-43412.
Chen, G.; Liu, H.; Zhang, Y.; Liang, J.; Zhu, Y.; Zhang, M.; Yu, D.; Wang, C.; Hou, J. Silencing PFKP inhibits starvation-induced autophagy, glycolysis, and epithelial mesenchymal transition in oral squamous cell carcinoma. Exp. Cell Res., 2018, 370(1), 46-57.
Kim, N.H.; Cha, Y.H.; Lee, J.; Lee, S.H.; Yang, J.H.; Yun, J.S.; Cho, E.S.; Zhang, X.; Nam, M.; Kim, N.; Yuk, Y.S.; Cha, S.Y.; Lee, Y.; Ryu, J.K.; Park, S.; Cheong, J.H.; Kang, S.W.; Kim, S.Y.; Hwang, G.S.; Yook, J.I.; Kim, H.S. Snail reprograms glucose metabolism by repressing phosphofructokinase PFKP allowing cancer cell survival under metabolic stress. Nat. Commun., 2017, 8, 14374.
Zhou, K.; Yao, Y.L.; He, Z.C.; Chen, C.; Zhang, X.N.; Yang, K.D.; Liu, Y.Q.; Liu, Q.; Fu, W.J.; Chen, Y.P.; Niu, Q.; Ma, Q.H.; Zhou, R.; Yao, X.H.; Zhang, X.; Cui, Y.H.; Bian, X.W.; Shi, Y.; Ping, Y.F. VDAC2 interacts with PFKP to regulate glucose metabolism and phenotypic reprogramming of glioma stem cells. Cell Death Dis., 2018, 9(10), 988.
Bachem, M.G.; Schneider, E.; Gross, H.; Weidenbach, H.; Schmid, R.M.; Menke, A.; Siech, M.; Beger, H.; Grunert, A.; Adler, G. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology, 1998, 115(2), 421-432.
Gao, Z.; Wang, X.; Wu, K.; Zhao, Y.; Hu, G. Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/CXCR4 axis. Pancreatology, 2010, 10(2-3), 186-193.
Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc., 2008, 3(6), 1101-1108.
Vanderlinde, R.E. Measurement of total lactate dehydrogenase activity. Ann. Clin. Lab. Sci., 1985, 15(1), 13-31.
Li, J.H.; Cao, G.; Ma, Q.Y.; Liu, H.; Li, W.; Han, L. The bidirectional interation between pancreatic cancer and diabetes. World J. Surg. Oncol., 2012, 10, 171.
Stevens, R.J.; Roddam, A.W.; Beral, V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br. J. Cancer, 2007, 96(3), 507-509.
Wang, Z.; Lai, S.T.; Xie, L.; Zhao, J.D.; Ma, N.Y.; Zhu, J.; Ren, Z.G.; Jiang, G.L. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res. Clin. Pract., 2014, 106(1), 19-26.
Wang, M.; Kirk, J.S.; Venkataraman, S.; Domann, F.E.; Zhang, H.J.; Schafer, F.Q.; Flanagan, S.W.; Weydert, C.J.; Spitz, D.R.; Buettner, G.R.; Oberley, L.W. Manganese superoxide dismutase suppresses hypoxic induction of hypoxia-inducible factor-1alpha and vascular endothelial growth factor. Oncogene, 2005, 24(55), 8154-8166.
Semenza, G.L. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr. Opin. Genet. Dev., 1998, 8(5), 588-594.
Wenger, R.H. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J., 2002, 16(10), 1151-1162.
Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab., 2006, 3(3), 177-185.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy